Revamping homoeopathy from Drug and Cosmetic Act of 1940 to New Drugs, Medical Devices and Cosmetics Bill, 2022; A perspective. of 1

Authors

DOI:

https://doi.org/10.51910/ijhdr.v21icf.1254

Keywords:

Drugs and Cosmetics Act 1940, Homoeopathy

Abstract

Government of India at its 72nd year of republic had drafted the new bill entitled “New Drugs, Medical Devices and Cosmetics Bill 2022” which seeks to replace the existing “Drugs and Cosmetics Act, 1940”. Earlier in this Act, Chapter V mentions the support of regulatory authority for Ayurveda, Siddha, Unani drug. However the new draft of bill includes Sowa Rigpa and Homoeopathic drugs and proposes to develop new innovative drugs by establishing their scientific research board. Owing to the new suggestions put forth in this new draft an opinion is addressed in this letter concerned with quality standards, drug proving trials, safety standards and efficacy standards for homoeopathic drugs.

Author Biography

Aditya Dilipkumar Patil, Dr. D Y Patil Homoeopathic Medical College and Research Center.

Assistant Professor, Dr D Y Patil Homoeopathic Medical College and Research Center, Pimpri, Pune, Maharashtra, India.

Downloads

Published

2023-01-09

How to Cite

Patil, A. D. (2023). Revamping homoeopathy from Drug and Cosmetic Act of 1940 to New Drugs, Medical Devices and Cosmetics Bill, 2022; A perspective. of 1. International Journal of High Dilution Research - ISSN 1982-6206, 21(cf), 85–88. https://doi.org/10.51910/ijhdr.v21icf.1254

Issue

Vol. 21 No. cf (2022)

Section

Letters to the Editor

License

Copyright (c) 2022 Aditya Dilipkumar Patil

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

<a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png" /></a><br />This work is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/">Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License</a>.

Most read articles by the same author(s)